Immunotherapy continues to show exciting promise in more effectively combating several tumour types.
Many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly to tumours.
It is thought that once the lymphocytes engage to cancer cells they will unfailingly destroy them, provided that inhibitory mechanisms are in check.
Results from a study published in Nature Communications, now reveal how cancer cells escape death by lymphocytes through the disruption of interferon-gamma signalling.
Co-first authored by Enrique J. Arenas and Alex Martínez-Sabadell, Post-doctoral Fellow and Graduate Student, respectively, of Joaquín Arribas' Growth Factors Group at VHIO, their findings show promise in potentiating future immune-based therapies against solid tumours.
Global research efforts centering on T cell-engaging therapies T-cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs), are heightening expectations for the more effective treatment of cancer.
"While these immune-based approaches have already been approved for the treatment of some haematologic malignancies, they fail to show efficacy in clinical studies with solid tumours.
This failure has previously been associated with the incapacity of T-cells to successfully target cancer cells directly. Up until now, little has been reported on the mechanisms adopted by tumours which enable them to resist T-cell attack.
This has been the focus of our present research," said Joaquín Arribas, co-Program Director of Preclinical and Translational Research at VHIO, ICREA Professor, CIBERONC Investigator, Director of the Hospital del Mar Medical Research Institute (IMIM), and Corresponding Author of this study.
He continued, "Several different strategies are now being implemented by the cancer research community to overcome these mechanisms of resistance. We aimed to go one step further by establishing whether more mechanisms exist that enable cancer cells to overcome the onslaught of targeted lymphocytes."
Using HER2-driven cell lines and PDXs, and a TCB and CAR targeting HER2, the investigators have now unmasked a novel mechanism of resistance to redirected T-cells.
Specifically, they have discovered that even when active cytotoxic cells are successfully delivered to tumour cells, the latter adopt a strategy to avoid their elimination by lymphocytes.
Findings suggest that the disruption of interferon-gamma signalling confers resistance and therefore promotes disease progression.
Interferon?gamma (IFN?γ) is a cytokine that assumes an important role in inducing and modulating an array of immune responses.
"It acts as an interrupter that controls cell death.
Certain cancer cells learn to switch off this pathway and thus survive the attack of lymphocytes. At present, there is no easy way of applying this discovery in clinical practice.
Namely, to effectively identify those patients who have this pathway turned off.
This represents a next step in our research; to develop a simple method to be able to do so," noted co-First Author, Enrique J. Arenas.
Previous research led by Joaquín Arribas published in Science Translational Medicine (2018) **, showed that the p95HER2-T-cell bispecific antibody can successfully guide lymphocytes directly to cancer cells for their targeted killing.
This direct delivery was achieved thanks to the p95HER2 protein, which is only located in tumour cells.
Representing a new therapeutic avenue and fresh hope for patients who have ceased to respond to current therapies, this novel immune-based approach can be used to tackle certain HER2 breast cancers through its exclusive targeting of cancerous cells.
Building on these findings, the investigators hope to launch a new clinical trial in 2024-25 to further advance CAR-T targeting in breast cancer.
"Driven by our discoveries, we aim to more precisely screen patients for enrollment in this clinical study, better predict when resistance will occur, and develop strategies to overcome the mechanisms that govern this resistance," concluded Joaquín Arribas.
This present research published today in Nature Communications also counted on the expertise and collaboration of investigators belonging to the VHIO-BBVA Foundation's Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI), and was supported through funding received from the Spanish Association against Cancer (Asociación Española contra el Cáncer - AECC), Breast Cancer Research Foundation (BCRF), and the Carlos III Health Institute (Instituto de Salud Carlos III - ISCIII).
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.